This is an open-label, parallel-dose study consisting of a 4-6 week screening period, a 6-month treatment period and a 6-month post-treatment follow-up period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]).
2. Participants should be on standard of care lipid-lowering medications per local guidelines.
You may not be if
1. Hemoglobin A1c (HbA1c) ≥ 8.5% at Screening.
2. Alanine aminotransferase or aspartate aminotransferase \> 2.0 × upper limit of normal.
3. Total bilirubin \> 1.5 upper limit of normal unless due to Gilbert's syndrome.
4. Estimated GFR \< 30 mL/min/1.73 m\^2.
Clareo Health | A Study to Assess the Safety, Tolerability and Efficacy of ION775
